In contrast, other variables, including the presence of angioedema, age, sex, body weight, duration of CSU, itch severity score, omalizumab dose, number of doses administered, CU Index IgE levels, and pre- or post-baseline medications, did not predict symptom recurrence (68). Here, IGHE is linked to angioedema.